Advertisement
Advertisement

TheBody.com/TheBodyPRO.com covers The 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)

Case Report: Homozygous CCR5 Delta-32 Protection Overcome by Infection With X4 Virus

March/April 2012

CROI 2012: Seattle, 5-8 March 2012

A sobering and important report documented the case study of a man who was homozygous for the CCR5 delta-32 mutation that generally provides effective protection against infection from HIV.

With most circulating (and infectious) virus using the CCR5 co-receptor, individuals with this deletion in both chromosomes who are exposed to HIV provide a dead-end for the infection, with the virus unable to infection CD4 cells without the use of the coreceptor.

This case of a 39 year-old man -- who was diagnosed in 1996 -- was indentified by Ester Ballana and colleagues after retrospectively testing DNA from stored peripheral blood mononuclear cells (PBMCs). The man had started treatment within 6 months of diagnosis, at a CD4 count of 520 and viral load of 3,500 copies/mL. Sequence analysis of the env gene idicated homogeneous X4 virus.

Fifteen years after seroconversion, total HIV-1 proviral DNA was 60 copies/million PBMCs. CD4 count had only increased to 600-700 over this time but HLA haplotype analysis showed multiple alleles associated with slower HIC progression including HLA-B*5701 and HLA-A*2402.


Reference

  1. Ballana E et al. HIV-1 infection in a CCR5-D32/D32, HLA-B*5701, and HLA-A*2402 subject: a case report. Poster abstract 292.

    www.retroconference.org/2012b/Abstracts/43778.htm

Links to external websites are current at time of posting but not maintained.




This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement